Scientific Sessions

Coronavirus infection can affect children of all ages in 2019. (COVID-19). However, most infected children do not develop as sick as adults, and some may exhibit no symptoms at all. Because of the lack of specificity of signs and symptoms, as well as the large number of asymptomatic infections, symptom-based screening for SARS-CoV-2 in children is particularly difficult. For children with severe or critical COVID-19, supportive care (e.g., respiratory assistance, hydration and electrolyte support, and monitoring for cytokine release syndrome) is the basis of treatment. Although the majority of COVID-19 vaccinations are only licenced for adults over the age of 18, a growing number of vaccines are being approved for use in youngsters. mRNA vaccines for use in the adolescent age range have been awarded emergency use authorisation in some countries (aged 12-17 years). Two inactivated vaccines (Sinovac-CoronaVac and BBIBP-CorV) have completed trials in children as young as three years old, and these products have been licenced by Chinese authorities for the age range of three to seventeen years.